Tapentadol in neuropathic pain cancer patients: a prospective open label study
Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN...
Saved in:
| Published in | Neurological sciences Vol. 38; no. 10; pp. 1747 - 1752 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Milan
Springer Milan
01.10.2017
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way (
p
< 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. |
|---|---|
| AbstractList | Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way (p < 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way ( p < 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way (p < 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way (p < 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy.Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day. All patients underwent pain intensity (NRS) and DN4. For evaluation of quality of life, patients underwent EORTC QLQ-C30 and EORTC QLQ-CIPN2 QLQ-CIPN20. We enrolled 31 patients, 19 were females with a median age of 60 years. After 3 months of treatment with TP, 22 patients completed the statistical package for social sciences (SPSS). Nineteen patients out of 22 showed a response to treatment (86%). We also observed that TP reduced the NRS and DN4 values from baseline to the last visit in a significant way (p < 0.001, respectively). Seven patients (22.5%) discontinued the TP therapy after the first week of occurrence of side effects. Furthermore, we observed that TP improved also the global health status measured by EORT QLQ-C30. TP is well tolerated and efficacy in the treatment of NP. The important reduction of neuropathic pain, the improvement in NRS and QoL scores after therapy with TP makes it a candidate in the management of patients suffering from neuropathic pain of CIPN also as a first line of therapy. |
| Author | Terrenato, Irene Pace, Andrea Villani, Veronica Galiè, Edvina |
| Author_xml | – sequence: 1 givenname: Edvina orcidid: 0000-0001-8837-4258 surname: Galiè fullname: Galiè, Edvina email: edvina.galie@ifo.gov.it organization: Neuro-Oncology Unit, “Regina Elena” National Cancer Institute – sequence: 2 givenname: Veronica surname: Villani fullname: Villani, Veronica organization: Neuro-Oncology Unit, “Regina Elena” National Cancer Institute – sequence: 3 givenname: Irene surname: Terrenato fullname: Terrenato, Irene organization: Biostatistic Unit-Scientific Direction, “Regina Elena” National Cancer Institute – sequence: 4 givenname: Andrea surname: Pace fullname: Pace, Andrea organization: Neuro-Oncology Unit, “Regina Elena” National Cancer Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28699105$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9LxDAQxYOsqLv6AbxIwYuXatIkTeJNxH-w6GU9hzSdaqWb1iQV_PZm2VVkQS_JEH5v8mbeFE1c7wChY4LPCcbiIqzOIsdE5BRTnpMddEC4wjllQk42NZGC7aNpCG8YY8II3UP7hSyVIpgfoMeFGcBFU_dd1rrMwej7wcTX1maDSQ_WOAs-1bFNWLjMTDb4PgxgY_sBWZ_EWWcq6LIQx_rzEO02pgtwtLln6Pn2ZnF9n8-f7h6ur-a5pUrGHGhTMcGo4IZaBYY2pS25aFghGS5NzQlUsmSWpwGVqDilRtYWlIQSNxVwOkNn677JzPsIIeplGyx0nXHQj0ETRSSVpJBFQk-30Ld-9C65SxTDjHMlSaJONtRYLaHWg2-Xxn_q700lgKwBm8YPHpofhGC9ykGv09ApDb1KQ6-aii2NbWPaZO-iN233r7JYK0P6xb2A_2X6T9EXskiceQ |
| CitedBy_id | crossref_primary_10_1212_CON_0000000000000928 crossref_primary_10_1007_s10072_018_3575_z crossref_primary_10_1007_s00520_022_06992_w crossref_primary_10_1007_s00540_020_02821_8 crossref_primary_10_17116_onkolog20241305176 crossref_primary_10_1016_j_biopha_2022_113871 crossref_primary_10_1097_SPC_0000000000000641 crossref_primary_10_1111_bph_14580 crossref_primary_10_1155_2019_2091960 crossref_primary_10_1177_15347354221121095 crossref_primary_10_3390_cancers14164002 |
| Cites_doi | 10.1016/S1470-2045(10)70068-1 10.1016/j.critrevonc.2008.01.008 10.1016/j.neulet.2011.01.014 10.1007/s11136-013-0379-8 10.1185/03007995.2014.894501 10.1016/j.neulet.2011.12.008 10.1016/S0959-8049(02)00229-0 10.1016/j.ejpain.2009.01.005 10.3324/haematol.2009.012674 10.1185/03007995.2012.739151 10.1002/ejp.598 10.2147/DHPS.S28829 10.3344/kjp.2010.23.2.99 10.1185/03007995.2014.934793 10.1185/03007995.2011.611494 10.2147/JPR.S14842 10.1016/j.ejpain.2010.06.017 10.1016/S1474-4422(10)70143-5 10.1177/1049909111434634 10.5055/jom.2010.0020 10.1177/0269216312464408 10.1185/03007995.2012.679254 10.2147/JPR.S83490 10.1111/papr.12018 10.2147/JPR.S72150 10.1111/j.1529-8027.2008.00156.x 10.4065/mcp.2009.0649 10.1124/mol.113.091520 10.1186/1756-6606-4-31 10.1111/j.1468-1331.2010.02999.x 10.2147/TCRM.S32193 10.1016/j.pain.2011.10.028 10.1200/JCO.2013.52.0536 10.1002/cncr.24384 10.1016/j.jclinepi.2015.08.007 10.1016/j.pain.2004.09.012 10.1038/nrc2167-c1 10.2147/JPR.S19625 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag Italia S.r.l. 2017 Neurological Sciences is a copyright of Springer, 2017. |
| Copyright_xml | – notice: Springer-Verlag Italia S.r.l. 2017 – notice: Neurological Sciences is a copyright of Springer, 2017. |
| DBID | AAYXX CITATION NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9- K9. M0R M0S M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1007/s10072-017-3035-1 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Consumer Health Database ProQuest Health & Medical Collection Medical Database Psychology Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central (subscription) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1590-3478 |
| EndPage | 1752 |
| ExternalDocumentID | 28699105 10_1007_s10072_017_3035_1 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 2.D 203 29N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACUDM ACUHS ACZOJ ADBBV ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADPHR ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN AZQEC B-. B0M BA0 BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EAD EAP EAS EBC EBD EBLON EBS EBX ECV EHN EIOEI EJD EMB EMK EMOBN EN4 ENC ENX EPAXT EPL EPS EPT ESBYG ESX F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KPH LAS LLZTM M0R M1P M2M M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOR QOS Q~Q R89 R9I RIG ROL RPX RRX RSV S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC TUS U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ~8M ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT NPM 7TK 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c398t-e3fb474375a3c9ea3f6c657f428406ad51eb864c510097b533a8dce98e60fbe53 |
| IEDL.DBID | U2A |
| ISSN | 1590-1874 1590-3478 |
| IngestDate | Thu Jul 10 17:54:34 EDT 2025 Sat Aug 16 05:21:04 EDT 2025 Wed Feb 19 02:43:16 EST 2025 Thu Apr 24 22:53:10 EDT 2025 Tue Jul 01 00:41:37 EDT 2025 Fri Feb 21 02:36:54 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Pain Neuropathy Tapentadol Cancer |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c398t-e3fb474375a3c9ea3f6c657f428406ad51eb864c510097b533a8dce98e60fbe53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8837-4258 |
| PMID | 28699105 |
| PQID | 1940455981 |
| PQPubID | 27321 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1918381282 proquest_journals_1940455981 pubmed_primary_28699105 crossref_primary_10_1007_s10072_017_3035_1 crossref_citationtrail_10_1007_s10072_017_3035_1 springer_journals_10_1007_s10072_017_3035_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-01 |
| PublicationDateYYYYMMDD | 2017-10-01 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Milan |
| PublicationPlace_xml | – name: Milan – name: Italy – name: Milano |
| PublicationSubtitle | Official Journal of the Italian Neurological Society |
| PublicationTitle | Neurological sciences |
| PublicationTitleAbbrev | Neurol Sci |
| PublicationTitleAlternate | Neurol Sci |
| PublicationYear | 2017 |
| Publisher | Springer Milan Springer Nature B.V |
| Publisher_xml | – name: Springer Milan – name: Springer Nature B.V |
| References | Dworkin, O'Connor, Audette, Baron, Gourlay, Haanpää, Kent, Krane, Lebel, Levy, Mackey, Mayer, Miaskowski, Raja, Rice, Schmader, StaceyB, Treede, Turk, Walco, Wells (CR16) 2010; 85 Giesinger, Kieffer, Fayers, Groenvold, Petersen, Scott, Sprangers, Velikova, Aaronson (CR34) 2016; 69 Argyriou, Koltzenburg, Polychronopoulos, Papapetropoulos, Kalofonos (CR6) 2008; 66 Prommer (CR23) 2010; 6 Beijers, Jongen, Vreugdenhil (CR13) 2012; 70 Coluzzi, Ruggeri (CR36) 2014; 30 Vadivelu, Timchenko, Huang, Sinatra (CR29) 2011; 4 Steigerwald, Müller, Davies, Samper, Sabatowski, Baron, Rozenberg, Szczepanska-Szerej, Gatti, Kress (CR26) 2012; 28 Dworkin, Turk, Farrar, Haythornthwaite, Jensen, Katz, Kerns, Stucki, Allen, Bellamy, Carr, Chandler, Cowan, Dionne, Galer, Hertz, Jadad, Kramer, Manning, Martin, McCormick, McDermott, McGrath, Quessy, Rappaport, Robbins, Robinson, Rothman, Royal, Simon, Stauffer, Stein, Tollett, Wernicke, Witter (CR31) 2005; 113 Meneghini, Cuccurazzu, Bortolotto, Ramazzotti, Ubezio, Tzschentke, Canonico, Grilli (CR40) 2014; 85 Cassier, Walter, Eymard, Ardisson, Perol, Paillet, Chayvialle, Scoazec, Hervieu, Bohas (CR8) 2009; 115 Zhuo, Wu, Wu (CR12) 2011; 4 Kögel, De Vry, Tzschentke, Christoph (CR39) 2011; 17 Kress (CR30) 2010; 14 Van Seventer, Vos, Meerding, Mear, Le Gal, Bouhassira, Huygen (CR32) 2010; 14 Attal, Cruccu, Baron, Haanpää, Hansson, Jensen, Nurmikko (CR15) 2010; 17 Mohty, El-Cheikh, Yakoub-Agha, Moreau, Harousseau, Mohty (CR37) 2010; 95 Piano, Verhagen, Schalkwijk, Burgers, Kress, Treede, Hekster, Lanteri-Minet, Engels, Vissers (CR1) 2013; 13 Loprinzi, Qin, Dakhil, Fehrenbacher, Flynn, Atherton, Seisler, Qamar, Lewis, Grothey (CR14) 2014; 32 Riemsma, Forbes, Harker, Worthy, Misso, Schäfer, Kleijnen, Stürzebecher (CR24) 2011; 27 Vadivelu, Huang, Mirante, Jacoby, Braveman, Hines, Sinatra (CR28) 2013; 5 Bennett, Rayment, Hjermstad, Aass, Caraceni, Kaasa (CR9) 2012; 153 Pergolizzi, Alon, Baron, Bonezzi, Dobrogowski, Gálvez, Jensen, Kress, Marcus, Morlion, Perrot, Treede (CR21) 2011; 203 Pierce, Shipstone (CR22) 2012; 29 Cavaletti, Zanna (CR4) 2002; 38 CR7 Rayment, Hjermstad, Aass, Kaasa, Caraceni, Strasser, Heitzer, Fainsinger, Bennett (CR5) 2013; 27 Tzschentke, Folgering, Flik, De Vry (CR38) 2012; 24 Delforge, Bladé, Dimopoulos, Facon, Kropff, Ludwig, Palumbo, Van Damme, San-Miguel, Sonneveld (CR2) 2010; 11 Baron, Binder, Wasner (CR11) 2010; 9 Windebank, Grisold (CR3) 2008; 13 Coluzzi, Raffa, Pergolizzi, Rocco, Locarini, Cenfra, Cimino, Mattia (CR18) 2015; 8 Mercadante, Porzio, Adile, Aielli, Cortegiani, Dickenson, Casuccio (CR20) 2014; 30 Vadivelu, Kai, Maslin, Kodumudi, Legler, Berger (CR27) 2015; 11 Schikowski, Krings, Schwenke (CR25) 2014; 8 Merskey, Bogduk (CR10) 1994 Pérez, Sánchez-Martínez, Ballesteros, Blanco, Collazo, González, Villoria (CR33) 2015; 19 Park, Moon (CR17) 2010; 23 Lavoie Smith, Barton, Qin, Steen, Aaronson, Loprinzi (CR35) 2013; 22 Mercadante, Porzio, Ferrera, Aielli, Adile, Ficorella, Giarratano, Casuccio (CR19) 2012; 28 R Seventer Van (3035_CR32) 2010; 14 DM Pierce (3035_CR22) 2012; 29 HG Kress (3035_CR30) 2010; 14 AJ Windebank (3035_CR3) 2008; 13 N Vadivelu (3035_CR29) 2011; 4 CL Loprinzi (3035_CR14) 2014; 32 TM Tzschentke (3035_CR38) 2012; 24 A Schikowski (3035_CR25) 2014; 8 R Riemsma (3035_CR24) 2011; 27 3035_CR7 C Pérez (3035_CR33) 2015; 19 V Meneghini (3035_CR40) 2014; 85 B Kögel (3035_CR39) 2011; 17 N Vadivelu (3035_CR27) 2015; 11 M Delforge (3035_CR2) 2010; 11 I Steigerwald (3035_CR26) 2012; 28 PA Cassier (3035_CR8) 2009; 115 N Vadivelu (3035_CR28) 2013; 5 JM Giesinger (3035_CR34) 2016; 69 B Mohty (3035_CR37) 2010; 95 V Piano (3035_CR1) 2013; 13 H Merskey (3035_CR10) 1994 M Zhuo (3035_CR12) 2011; 4 F Coluzzi (3035_CR36) 2014; 30 MI Bennett (3035_CR9) 2012; 153 AJ Beijers (3035_CR13) 2012; 70 AA Argyriou (3035_CR6) 2008; 66 R Baron (3035_CR11) 2010; 9 HJ Park (3035_CR17) 2010; 23 S Mercadante (3035_CR20) 2014; 30 G Cavaletti (3035_CR4) 2002; 38 EM Lavoie Smith (3035_CR35) 2013; 22 EE Prommer (3035_CR23) 2010; 6 RH Dworkin (3035_CR16) 2010; 85 N Attal (3035_CR15) 2010; 17 S Mercadante (3035_CR19) 2012; 28 J Pergolizzi (3035_CR21) 2011; 203 F Coluzzi (3035_CR18) 2015; 8 RH Dworkin (3035_CR31) 2005; 113 C Rayment (3035_CR5) 2013; 27 21232580 - Neurosci Lett. 2011 Mar 17;491(2):104-7 21801430 - Mol Brain. 2011 Jul 30;4:31 24516101 - Mol Pharmacol. 2014 May;85(5):658-70 20659810 - Eur J Pain. 2010 Sep;14(8):781-3 25265909 - Eur J Pain. 2015 Jul;19(6):752-61 12204664 - Eur J Cancer. 2002 Sep;38(14):1832-7 25609974 - Ther Clin Risk Manag. 2015 Jan 14;11:95-105 21887118 - J Pain Res. 2011;4:211-8 18346229 - J Peripher Nerv Syst. 2008 Mar;13(1):27-46 23543373 - Qual Life Res. 2013 Dec;22(10):2787-99 26327487 - J Clin Epidemiol. 2016 Jan;69:79-88 20556211 - Korean J Pain. 2010 Jun;23(2):99-108 21905968 - Curr Med Res Opin. 2011 Oct;27(10):1907-30 26064064 - J Pain Res. 2015 May 08;8:229-38 20194146 - Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14 22197547 - Neurosci Lett. 2012 Jan 24;507(2):151-5 23175513 - Palliat Med. 2013 Sep;27(8):714-21 20932799 - Lancet Oncol. 2010 Nov;11(11):1086-95 19282208 - Eur J Pain. 2010 Jan;14(1):58-63 22310021 - Am J Hosp Palliat Care. 2012 Dec;29(8):663-6 21887117 - J Pain Res. 2011;4:203-10 24297951 - J Clin Oncol. 2014 Apr 1;32(10):997-1005 22443293 - Curr Med Res Opin. 2012 Jun;28(6):911-36 22115921 - Pain. 2012 Feb;153(2):359-65 20139393 - Haematologica. 2010 Feb;95(2):311-9 25565884 - J Pain Res. 2014 Dec 22;8:1-8 20642251 - J Opioid Manag. 2010 May-Jun;6(3):223-6 23057488 - Curr Med Res Opin. 2012 Nov;28(11):1775-9 19472402 - Cancer. 2009 Aug 1;115(15):3392-9 18329278 - Crit Rev Oncol Hematol. 2008 Jun;66(3):218-28 20402746 - Eur J Neurol. 2010 Sep;17(9):1113-e88 20650402 - Lancet Neurol. 2010 Aug;9(8):807-19 15621359 - Pain. 2005 Jan;113(1-2):9-19 23861601 - Drug Healthc Patient Saf. 2013 Jul 03;5:151-9 18159632 - Nat Rev Cancer. 2008 Jan;8(1):1p following 71; author reply 1p following 71 24926734 - Curr Med Res Opin. 2014 Oct;30(10):2063-8 22271810 - Neth J Med. 2012 Jan;70(1):18-25 24528146 - Curr Med Res Opin. 2014 Jun;30(6):1139-51 23279302 - Pain Pract. 2013 Jul;13(6):433-9 |
| References_xml | – volume: 11 start-page: 1086 year: 2010 end-page: 1095 ident: CR2 article-title: Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70068-1 – volume: 66 start-page: 218 year: 2008 end-page: 228 ident: CR6 article-title: Peripheral nerve damage associated with administration of taxanes in patients with cancer publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2008.01.008 – volume: 203 start-page: 210 year: 2011 ident: CR21 article-title: Tapentadol in the management of chronic low back pain: a novel approach to a complex condition publication-title: J Pain Res – volume: 17 start-page: 104 issue: 491 year: 2011 end-page: 107 ident: CR39 article-title: The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor)knockout mice publication-title: Neurosci Lett doi: 10.1016/j.neulet.2011.01.014 – volume: 22 start-page: 2787 year: 2013 end-page: 2799 ident: CR35 article-title: Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire publication-title: Qual Life Res doi: 10.1007/s11136-013-0379-8 – volume: 30 start-page: 1139 year: 2014 end-page: 1151 ident: CR36 article-title: Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.894501 – volume: 24 start-page: 151 issue: 507 year: 2012 end-page: 155 ident: CR38 article-title: Tapentadol increases levels of noradrenaline in the rat spinal cord as measured byin vivo microdialysis publication-title: Neurosci Lett doi: 10.1016/j.neulet.2011.12.008 – volume: 38 start-page: 1832 year: 2002 end-page: 1837 ident: CR4 article-title: Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity publication-title: Eur J Cancer doi: 10.1016/S0959-8049(02)00229-0 – volume: 14 start-page: 58 year: 2010 end-page: 63 ident: CR32 article-title: Linguistic validation of the DN4 for use in international studies publication-title: Eur J Pain doi: 10.1016/j.ejpain.2009.01.005 – volume: 95 start-page: 311 year: 2010 end-page: 319 ident: CR37 article-title: Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations publication-title: Haematologica doi: 10.3324/haematol.2009.012674 – volume: 70 start-page: 18 year: 2012 end-page: 25 ident: CR13 article-title: Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies publication-title: Neth J Med – volume: 28 start-page: 1775 year: 2012 end-page: 1779 ident: CR19 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.739151 – volume: 19 start-page: 752 year: 2015 end-page: 761 ident: CR33 article-title: Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study publication-title: Eur J Pain doi: 10.1002/ejp.598 – volume: 5 start-page: 151 year: 2013 end-page: 159 ident: CR28 article-title: Patient considerations in the use of tapentadol for moderate to severe pain publication-title: Drug Healthc Patient Saf doi: 10.2147/DHPS.S28829 – volume: 23 start-page: 99 year: 2010 end-page: 108 ident: CR17 article-title: Pharmacologic Management of Chronic Pain publication-title: Korean J Pain doi: 10.3344/kjp.2010.23.2.99 – volume: 30 start-page: 2063 year: 2014 end-page: 2068 ident: CR20 article-title: Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.934793 – start-page: 209 year: 1994 end-page: 214 ident: CR10 article-title: Part III: pain terms, a current list with definitions and notes on usage publication-title: Classification of chronic pain, IASP task force on taxonomy – volume: 27 start-page: 1907 year: 2011 end-page: 1930 ident: CR24 article-title: Systemic review of tapentadol in chronic severe pain publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.611494 – volume: 4 start-page: 211 year: 2011 end-page: 218 ident: CR29 article-title: Tapentadol extended-release for treatment of chronic pain: a review publication-title: J Pain Res doi: 10.2147/JPR.S14842 – volume: 14 start-page: 781 year: 2010 end-page: 783 ident: CR30 article-title: Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? publication-title: Eur J Pain doi: 10.1016/j.ejpain.2010.06.017 – volume: 9 start-page: 807 year: 2010 end-page: 819 ident: CR11 article-title: Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70143-5 – volume: 29 start-page: 663 year: 2012 end-page: 666 ident: CR22 article-title: Pharmacology update: tapentadol for neurophatic pain publication-title: Am J Hosp Palliat Care doi: 10.1177/1049909111434634 – volume: 6 start-page: 223 year: 2010 end-page: 226 ident: CR23 article-title: Tapentadol: an initial analysis publication-title: J Opioid Manag J Opioid Manag doi: 10.5055/jom.2010.0020 – volume: 27 start-page: 714 year: 2013 end-page: 721 ident: CR5 article-title: Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative—computerised symptom assessment study publication-title: Palliat Med doi: 10.1177/0269216312464408 – volume: 28 start-page: 911 year: 2012 end-page: 936 ident: CR26 article-title: Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of open-label, phase 3b study publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.679254 – volume: 8 start-page: 229 year: 2015 end-page: 238 ident: CR18 article-title: Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease publication-title: J Pain Res doi: 10.2147/JPR.S83490 – volume: 13 start-page: 433 year: 2013 end-page: 439 ident: CR1 article-title: Diagnosing neuropathic pain in patients with cancer: comparative analysis of recommendations in national guidelines from European countries publication-title: Pain Pract doi: 10.1111/papr.12018 – ident: CR7 – volume: 8 start-page: 1 year: 2014 end-page: 8 ident: CR25 article-title: Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients publication-title: J Pain Res doi: 10.2147/JPR.S72150 – volume: 13 start-page: 27 year: 2008 end-page: 46 ident: CR3 article-title: Chemotherapy-induced neuropathy publication-title: J Peripheral Nerv Syst doi: 10.1111/j.1529-8027.2008.00156.x – volume: 85 start-page: S3 issue: 3 Suppl year: 2010 end-page: 14 ident: CR16 article-title: Recommendations for the pharmacological management of neuropathic pain: an overview and literature update publication-title: Mayo Clin Proc doi: 10.4065/mcp.2009.0649 – volume: 85 start-page: 658 year: 2014 end-page: 670 ident: CR40 article-title: The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis publication-title: Mol Pharmacol doi: 10.1124/mol.113.091520 – volume: 4 start-page: 1.51 year: 2011 ident: CR12 article-title: Neuronal and microglial mechanisms of neuropathic pain publication-title: Mol Brain doi: 10.1186/1756-6606-4-31 – volume: 17 start-page: 1113 year: 2010 end-page: 1123 ident: CR15 article-title: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision publication-title: European Journal of Neurology doi: 10.1111/j.1468-1331.2010.02999.x – volume: 11 start-page: 95 year: 2015 end-page: 105 ident: CR27 article-title: Tapentadol extended release in the management of peripheral diabetic neuropathic pain publication-title: Ther Clin Risk Manag doi: 10.2147/TCRM.S32193 – volume: 153 start-page: 359 year: 2012 end-page: 365 ident: CR9 article-title: Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review publication-title: Pain doi: 10.1016/j.pain.2011.10.028 – volume: 32 start-page: 997 year: 2014 end-page: 1005 ident: CR14 article-title: Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance) publication-title: J Clin Oncol doi: 10.1200/JCO.2013.52.0536 – volume: 115 start-page: 3392 year: 2009 end-page: 3399 ident: CR8 article-title: Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience publication-title: Cancer doi: 10.1002/cncr.24384 – volume: 69 start-page: 79 year: 2016 end-page: 88 ident: CR34 article-title: Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2015.08.007 – volume: 113 start-page: 9 year: 2005 end-page: 19 ident: CR31 article-title: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations publication-title: Pain doi: 10.1016/j.pain.2004.09.012 – ident: 3035_CR7 doi: 10.1038/nrc2167-c1 – volume: 4 start-page: 211 year: 2011 ident: 3035_CR29 publication-title: J Pain Res doi: 10.2147/JPR.S14842 – volume: 9 start-page: 807 year: 2010 ident: 3035_CR11 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70143-5 – volume: 85 start-page: 658 year: 2014 ident: 3035_CR40 publication-title: Mol Pharmacol doi: 10.1124/mol.113.091520 – volume: 11 start-page: 95 year: 2015 ident: 3035_CR27 publication-title: Ther Clin Risk Manag doi: 10.2147/TCRM.S32193 – volume: 13 start-page: 433 year: 2013 ident: 3035_CR1 publication-title: Pain Pract doi: 10.1111/papr.12018 – volume: 113 start-page: 9 year: 2005 ident: 3035_CR31 publication-title: Pain doi: 10.1016/j.pain.2004.09.012 – volume: 24 start-page: 151 issue: 507 year: 2012 ident: 3035_CR38 publication-title: Neurosci Lett doi: 10.1016/j.neulet.2011.12.008 – volume: 70 start-page: 18 year: 2012 ident: 3035_CR13 publication-title: Neth J Med – volume: 14 start-page: 781 year: 2010 ident: 3035_CR30 publication-title: Eur J Pain doi: 10.1016/j.ejpain.2010.06.017 – volume: 203 start-page: 210 year: 2011 ident: 3035_CR21 publication-title: J Pain Res doi: 10.2147/JPR.S19625 – volume: 23 start-page: 99 year: 2010 ident: 3035_CR17 publication-title: Korean J Pain doi: 10.3344/kjp.2010.23.2.99 – volume: 29 start-page: 663 year: 2012 ident: 3035_CR22 publication-title: Am J Hosp Palliat Care doi: 10.1177/1049909111434634 – volume: 27 start-page: 714 year: 2013 ident: 3035_CR5 publication-title: Palliat Med doi: 10.1177/0269216312464408 – volume: 28 start-page: 1775 year: 2012 ident: 3035_CR19 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.739151 – volume: 85 start-page: S3 issue: 3 Suppl year: 2010 ident: 3035_CR16 publication-title: Mayo Clin Proc doi: 10.4065/mcp.2009.0649 – volume: 19 start-page: 752 year: 2015 ident: 3035_CR33 publication-title: Eur J Pain doi: 10.1002/ejp.598 – volume: 8 start-page: 229 year: 2015 ident: 3035_CR18 publication-title: J Pain Res doi: 10.2147/JPR.S83490 – volume: 5 start-page: 151 year: 2013 ident: 3035_CR28 publication-title: Drug Healthc Patient Saf doi: 10.2147/DHPS.S28829 – volume: 95 start-page: 311 year: 2010 ident: 3035_CR37 publication-title: Haematologica doi: 10.3324/haematol.2009.012674 – volume: 22 start-page: 2787 year: 2013 ident: 3035_CR35 publication-title: Qual Life Res doi: 10.1007/s11136-013-0379-8 – volume: 8 start-page: 1 year: 2014 ident: 3035_CR25 publication-title: J Pain Res doi: 10.2147/JPR.S72150 – volume: 28 start-page: 911 year: 2012 ident: 3035_CR26 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.679254 – start-page: 209 volume-title: Classification of chronic pain, IASP task force on taxonomy year: 1994 ident: 3035_CR10 – volume: 69 start-page: 79 year: 2016 ident: 3035_CR34 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2015.08.007 – volume: 17 start-page: 1113 year: 2010 ident: 3035_CR15 publication-title: European Journal of Neurology doi: 10.1111/j.1468-1331.2010.02999.x – volume: 6 start-page: 223 year: 2010 ident: 3035_CR23 publication-title: J Opioid Manag J Opioid Manag doi: 10.5055/jom.2010.0020 – volume: 32 start-page: 997 year: 2014 ident: 3035_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.52.0536 – volume: 14 start-page: 58 year: 2010 ident: 3035_CR32 publication-title: Eur J Pain doi: 10.1016/j.ejpain.2009.01.005 – volume: 153 start-page: 359 year: 2012 ident: 3035_CR9 publication-title: Pain doi: 10.1016/j.pain.2011.10.028 – volume: 30 start-page: 1139 year: 2014 ident: 3035_CR36 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.894501 – volume: 17 start-page: 104 issue: 491 year: 2011 ident: 3035_CR39 publication-title: Neurosci Lett doi: 10.1016/j.neulet.2011.01.014 – volume: 30 start-page: 2063 year: 2014 ident: 3035_CR20 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.934793 – volume: 4 start-page: 1.51 year: 2011 ident: 3035_CR12 publication-title: Mol Brain doi: 10.1186/1756-6606-4-31 – volume: 27 start-page: 1907 year: 2011 ident: 3035_CR24 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.611494 – volume: 115 start-page: 3392 year: 2009 ident: 3035_CR8 publication-title: Cancer doi: 10.1002/cncr.24384 – volume: 38 start-page: 1832 year: 2002 ident: 3035_CR4 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(02)00229-0 – volume: 13 start-page: 27 year: 2008 ident: 3035_CR3 publication-title: J Peripheral Nerv Syst doi: 10.1111/j.1529-8027.2008.00156.x – volume: 66 start-page: 218 year: 2008 ident: 3035_CR6 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2008.01.008 – volume: 11 start-page: 1086 year: 2010 ident: 3035_CR2 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70068-1 – reference: 23861601 - Drug Healthc Patient Saf. 2013 Jul 03;5:151-9 – reference: 25609974 - Ther Clin Risk Manag. 2015 Jan 14;11:95-105 – reference: 23279302 - Pain Pract. 2013 Jul;13(6):433-9 – reference: 20402746 - Eur J Neurol. 2010 Sep;17(9):1113-e88 – reference: 18159632 - Nat Rev Cancer. 2008 Jan;8(1):1p following 71; author reply 1p following 71 – reference: 23175513 - Palliat Med. 2013 Sep;27(8):714-21 – reference: 24297951 - J Clin Oncol. 2014 Apr 1;32(10):997-1005 – reference: 23057488 - Curr Med Res Opin. 2012 Nov;28(11):1775-9 – reference: 20194146 - Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14 – reference: 18329278 - Crit Rev Oncol Hematol. 2008 Jun;66(3):218-28 – reference: 22443293 - Curr Med Res Opin. 2012 Jun;28(6):911-36 – reference: 15621359 - Pain. 2005 Jan;113(1-2):9-19 – reference: 12204664 - Eur J Cancer. 2002 Sep;38(14):1832-7 – reference: 22197547 - Neurosci Lett. 2012 Jan 24;507(2):151-5 – reference: 18346229 - J Peripher Nerv Syst. 2008 Mar;13(1):27-46 – reference: 20556211 - Korean J Pain. 2010 Jun;23(2):99-108 – reference: 24528146 - Curr Med Res Opin. 2014 Jun;30(6):1139-51 – reference: 21801430 - Mol Brain. 2011 Jul 30;4:31 – reference: 25265909 - Eur J Pain. 2015 Jul;19(6):752-61 – reference: 21887117 - J Pain Res. 2011;4:203-10 – reference: 22115921 - Pain. 2012 Feb;153(2):359-65 – reference: 23543373 - Qual Life Res. 2013 Dec;22(10):2787-99 – reference: 19282208 - Eur J Pain. 2010 Jan;14(1):58-63 – reference: 20650402 - Lancet Neurol. 2010 Aug;9(8):807-19 – reference: 21232580 - Neurosci Lett. 2011 Mar 17;491(2):104-7 – reference: 19472402 - Cancer. 2009 Aug 1;115(15):3392-9 – reference: 26327487 - J Clin Epidemiol. 2016 Jan;69:79-88 – reference: 20139393 - Haematologica. 2010 Feb;95(2):311-9 – reference: 25565884 - J Pain Res. 2014 Dec 22;8:1-8 – reference: 24926734 - Curr Med Res Opin. 2014 Oct;30(10):2063-8 – reference: 21887118 - J Pain Res. 2011;4:211-8 – reference: 20932799 - Lancet Oncol. 2010 Nov;11(11):1086-95 – reference: 24516101 - Mol Pharmacol. 2014 May;85(5):658-70 – reference: 26064064 - J Pain Res. 2015 May 08;8:229-38 – reference: 20642251 - J Opioid Manag. 2010 May-Jun;6(3):223-6 – reference: 21905968 - Curr Med Res Opin. 2011 Oct;27(10):1907-30 – reference: 22310021 - Am J Hosp Palliat Care. 2012 Dec;29(8):663-6 – reference: 22271810 - Neth J Med. 2012 Jan;70(1):18-25 – reference: 20659810 - Eur J Pain. 2010 Sep;14(8):781-3 |
| SSID | ssj0001413 |
| Score | 2.2376409 |
| Snippet | Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1747 |
| SubjectTerms | Chemotherapy Medicine Medicine & Public Health Neurology Neuroradiology Neurosciences Neurosurgery Oncology Original Article Pain Peripheral neuropathy Psychiatry Quality of life Titration |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA86QXwRv61OieCTUuxX2tQXEXEMYXvaYG8lSVMQRlv38f97l6adMvS5aRLuktzvcpffEXKfKvABwD12g5SDg5JK3xVgCFwZB3mu_DwozPPo0TgeTqOPGZvZC7elTatsz0RzUOeVwjvyJ3C2AX0w6PGl_nKxahRGV20JjV2yh9RluKqTWedwYQ6jSbBnKcYvk6iNajZP57wEkxJgiyFro__bLm2Bza1AqbE_gyNyaIEjfW00fUx2dHlC9kc2NH5KxhNRYx54Xs3pZ0kNT6UpN6xoDd4_VajeBbU8qstnKigM3z60pFhFi8KK0HNqGGfPyHTwPnkburZYgqvClK9cHRYyAjiQMBGqVIuwiFXMkgLcC7DZIme-ljyOFOxBL00koDzBc6VTrmOvkJqF56RXVqW-JFQWhc-5APlEIgIbKiKmE4msNbHBFw7xWlFlyjKJY0GLebbhQEbpZiDdDKWbwS8P3S91Q6PxX-N-K__M7qhlttG_Q-66z7AXMMAhSl2tsQ0cUIBYeOCQi0Zv3WgBjwEKe8whj60if3T-11Su_p_KNTkIcAmZ5L4-6a0Wa30DIGUlb81K_AZQst9z priority: 102 providerName: ProQuest |
| Title | Tapentadol in neuropathic pain cancer patients: a prospective open label study |
| URI | https://link.springer.com/article/10.1007/s10072-017-3035-1 https://www.ncbi.nlm.nih.gov/pubmed/28699105 https://www.proquest.com/docview/1940455981 https://www.proquest.com/docview/1918381282 |
| Volume | 38 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFD7oBuKLeHc6RwSflEIvSZv6NmU6lA2RDeZTSdIUhNGNXf6_J1lbJ1PBpz40Scu55HyHcwO4jhX6AOgeO37M0UGJpecINASODP00VV7qZ7Y8utcPu0P6PGKjoo57Xma7lyFJe1OvFbu5kUkjQKUwfRbR5akzdN1NHtfQb1fXr0ftTGQ00yZoGdEylPnTEd-N0QbC3IiOWqPzuA97BVok7RV7D2BL54ew0yvi4UfQH4ipSf5OJ2PykRPbnNLOGFZkii4_UYanM1I0T53fEUHw82V1JTGjswiKgR4T22b2GIaPncFD1ykmJDgqiPnC0UEmKWKAiIlAxVoEWahCFmXoU6ChFinztOQhVah4bhxJhHaCp0rHXIduJjULTqCWT3J9BkRmmce5QPpQQdFwCsp0JE2rmtCCiga4JakSVbQPN1MsxslX42ND3QSpmxjqJrjlptoyXfXO-Gtxs6R_UqjRPPFiipCToRg14Kp6jQpgohoi15OlWYO3EsIU7jfgdMW36ms-DxH_uqwBtyUj1w7_7VfO_7X6AnZ9I1E2wa8JtcVsqS8RqCxkC7ajUdSCevvp_aWDz_tO__WtZcX1Ex323-c |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8NAEB6KgnoR31arrqAXJZikeWwEEVFLq21PFXqLu5sNCCWttiL-KX-jM5ukKkVvXpPsg9l5fJOZnQE4ihT6AOgeW27E0UGJpGMJNASWDNwkUU7ipuZ6dKcbNB-8u77fr8BHeReG0ipLnWgUdTJU9I_8DJ1tRB8-zng5eraoaxRFV8sWGjlb3Ov3N3TZxhetGzzfY9dt3Paum1bRVcBS9YhPLF1PpYd2M_RFXUVa1NNABX6YIg5H4yYS39GSB55CZrWjUCIcEjxROuI6sFOpqUsEqvx5NLw2OXthf-rgUc6kSej3I4qXhl4ZRc2v6tkhJUGgSFOVSOenHZwBtzOBWWPvGiuwXABVdpVz1ipUdLYGC50iFL8O3Z4YUd55Mhywp4yZupimvbFiI4EPFLHTCyvqto7PmWC4fHmxk1HXLoYcqAfMVLjdgId_IeMmzGXDTG8Dk2nqcC6QPp7w0GYLz9ehpCo5gcEzVbBLUsWqqFxODTQG8VfNZaJujNSNiboxDjmZDhnlZTv--rhW0j8uJHgcf_FbFQ6nr1H2KKAiMj18pW9QISJC4m4VtvJzm67m8gCht-1X4bQ8yG-T_7aVnb-3cgCLzV6nHbdb3ftdWHKJnUxiYQ3mJi-veg8B0kTuG65k8PjfYvAJ8FkcTQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8NAEB6kgngR31arrqAXJZikeWwEEbUtam0RUfAWdzcbEEpabYv41_x1zmySqojevCbZB7Pz-CYzOwOwGyn0AdA9ttyIo4MSSccSaAgsGbhJopzETc316E43uLj3rh78hyl4L-_CUFplqRONok76iv6RH6KzjejDxxkP0yIt4qbROhk8W9RBiiKtZTuNnEXa-u0V3bfh8WUDz3rPdVvNu_MLq-gwYKl6xEeWrqfSQxsa-qKuIi3qaaACP0wRk6OhE4nvaMkDTyHj2lEoERoJnigdcR3YqdTUMQLV_3RIXlEFps-a3ZvbiR1wPNOcGfECRU9Dr4yp5hf37JBSIlDAqWak890q_oC6P8K0xvq15mGugK3sNOezBZjS2SLMdIrA_BJ078SAstCTfo89ZcxUyTTNjhUbCHygiLleWFHFdXjEBMPly2uejHp4MeRH3WOm3u0y3P8LIVegkvUzvQZMpqnDuUD6eMJDCy48X4eSauYEBt1UwS5JFauijjm10-jFnxWYiboxUjcm6sY4ZH8yZJAX8fjr41pJ_7iQ52H8yX1V2Jm8Rkmk8IrIdH9M36B6RLzE3Sqs5uc2Wc3lAQJx26_CQXmQXyb_bSvrf29lG2ZQBOLry257A2Zd4iaTZViDyuhlrDcRLY3kVsGWDB7_WxI-AEvFIeg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tapentadol+in+neuropathic+pain+cancer+patients%3A+a+prospective+open+label+study&rft.jtitle=Neurological+sciences&rft.au=Gali%C3%A8%2C+Edvina&rft.au=Villani%2C+Veronica&rft.au=Terrenato%2C+Irene&rft.au=Pace%2C+Andrea&rft.date=2017-10-01&rft.issn=1590-1874&rft.eissn=1590-3478&rft.volume=38&rft.issue=10&rft.spage=1747&rft.epage=1752&rft_id=info:doi/10.1007%2Fs10072-017-3035-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s10072_017_3035_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1590-1874&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1590-1874&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1590-1874&client=summon |